No Data
No Data
When Will KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Breakeven?
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. KalVista Pharmaceuticals, Inc., a clinic
KalVista Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
KalVista Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on KalVista Pharma, Lowers Price Target to $20
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors gr
KalVista Pharmaceuticals: A Strong Buy on Strategic Growth and Promising Sebetralstat Prospects